Search

Your search keyword '"Cortes, Jorge E."' showing total 4,844 results
Start Over Author "Cortes, Jorge E."
4,844 results on '"Cortes, Jorge E."'

101. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia

Author

Cortes, Jorge E., Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Milojkovic, Dragana, le Coutre, Philipp, Garcia-Gutierrez, Valentin, Crescenzo, Rocco, Mamolo, Carla, Reisman, Arlene, Hochhaus, Andreas, Brümmendorf, Tim H., and the BFORE Study Investigators

Published
2019
Full Text
View/download PDF

103. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Author

Cortes, Jorge E., Heidel, Florian H., Hellmann, Andrzej, Fiedler, Walter, Smith, B. Douglas, Robak, Tadeusz, Montesinos, Pau, Pollyea, Daniel A., DesJardins, Pierre, Ottmann, Oliver, Ma, Weidong Wendy, Shaik, M. Naveed, Laird, A. Douglas, Zeremski, Mirjana, O’Connell, Ashleigh, Chan, Geoffrey, and Heuser, Michael

Published
2019
Full Text
View/download PDF

104. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Author

Cortes, Jorge E, Kantarjian, Hagop, Shah, Neil P, Bixby, Dale, Mauro, Michael J, Flinn, Ian, O'Hare, Thomas, Hu, Simin, Narasimhan, Narayana I, Rivera, Victor M, Clackson, Tim, Turner, Christopher D, Haluska, Frank G, Druker, Brian J, Deininger, Michael WN, and Talpaz, Moshe

Subjects
Pediatric, Hematology, Cancer, Rare Diseases, Clinical Research, Pediatric Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Amylases, Antineoplastic Agents, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Female, Follow-Up Studies, Fusion Proteins, bcr-abl, Humans, Imidazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lipase, Male, Middle Aged, Mutation, Pancreatitis, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein-Tyrosine Kinases, Pyridazines, Structure-Activity Relationship, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundResistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently caused by mutations in the BCR-ABL kinase domain. Ponatinib (AP24534) is a potent oral tyrosine kinase inhibitor that blocks native and mutated BCR-ABL, including the gatekeeper mutant T315I, which is uniformly resistant to tyrosine kinase inhibitors.MethodsIn this phase 1 dose-escalation study, we enrolled 81 patients with resistant hematologic cancers, including 60 with CML and 5 with Ph-positive ALL. Ponatinib was administered once daily at doses ranging from 2 to 60 mg. Median follow-up was 56 weeks (range, 2 to 140).ResultsDose-limiting toxic effects included elevated lipase or amylase levels and pancreatitis. Common adverse events were rash, myelosuppression, and constitutional symptoms. Among Ph-positive patients, 91% had received two or more approved tyrosine kinase inhibitors, and 51% had received all three approved tyrosine kinase inhibitors. Of 43 patients with chronic-phase CML, 98% had a complete hematologic response, 72% had a major cytogenetic response, and 44% had a major molecular response. Of 12 patients who had chronic-phase CML with the T315I mutation, 100% had a complete hematologic response and 92% had a major cytogenetic response. Of 13 patients with chronic-phase CML without detectable mutations, 100% had a complete hematologic response and 62% had a major cytogenetic response. Responses among patients with chronic-phase CML were durable. Of 22 patients with accelerated-phase or blast-phase CML or Ph-positive ALL, 36% had a major hematologic response and 32% had a major cytogenetic response.ConclusionsPonatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations. (Funded by Ariad Pharmaceuticals and others; ClinicalTrials.gov number, NCT00660920.).

Published
2012

105. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

Author

Yilmaz, Musa, Alfayez, Mansour, DiNardo, Courtney D., Borthakur, Gautam, Kadia, Tapan M., Konopleva, Marina Y., Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Patel, Keyur P., Jabbour, Elias J., Garcia-Manero, Guillermo, Pemmaraju, Naveen, Pierce, Sherry A., Ghayas, Issa, Short, Nicholas J., Montalban-Bravo, Guillermo, Takahashi, Koichi, Assi, Rita, Alotaibi, Ahmad S., Ohanian, Maro, Andreeff, Michael, Cortes, Jorge E., Kantarjian, Hagop M., Ravandi, Farhad, and Daver, Naval G.

Published
2020
Full Text
View/download PDF

109. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high‐risk myelodysplastic syndrome

Author

Lahoti, Amit, Kantarjian, Hagop, Salahudeen, Abdulla K, Ravandi, Farhad, Cortes, Jorge E, Faderl, Stefan, O'Brien, Susan, Wierda, William, and Mattiuzzi, Gloria N

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Rare Diseases, Pediatric, Hematology, Cancer, Childhood Leukemia, Pediatric Cancer, Kidney Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Renal and urogenital, Good Health and Well Being, Acute Kidney Injury, Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Kidney Function Tests, Leukemia, Myeloid, Acute, Male, Middle Aged, Myelodysplastic Syndromes, Prognosis, Risk Factors, acute kidney failure, acute myeloid leukemia, myelodysplastic syndrome, dialysis, logistic models, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

Background: Acute kidney injury (AKIis a common complication in the treatment of patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS), but, to the authors' knowledge, its clinical relevance has not been detailed to date. The objective of the current study was to identify the incidence, predictors, and outcome for AKI in patients with AML and HR-MDS.Methods: Data were analyzed from 537 patients with AML or HR-MDS undergoing induction chemotherapy from 1999 to 2007. Predictors for AKI were identified by logistic regression. Eight-week mortality of patients was estimated by the Kaplan-Meier method stratified by the RIFLE criteria, a novel multilevel classification system for AKI based on the percent rise in serum creatinine from baseline (Risk, >50%; Injury, >100%; and Failure, >200% or requiring dialysis).Results: A total of 187 patients (36%) developed AKI. Significant independent risk factors for AKI included the following: age >/=55 years (odds ratio [OR], 1.8), mechanical ventilation (OR, 16), use of vancomycin (OR, 2.3), diuretics (OR, 3.0), amphotericin B lipid formulation (OR, 2.7), vasopressors (OR, 4.9), leukopenia (OR, 1.9), hypoalbuminemia (OR, 1.4), and use of non-fludarabine-based chemotherapy (OR, 2.7). The 8-week mortality rates were 3.8%, 13.6%, 19.6%, and 61.7% for the non-RIFLE, Risk, Injury, and Failure categories, respectively. Patients requiring dialysis (8%) had a median survival of 33 days. Survival of patients who achieved complete remission was favorable, regardless of degree of AKI.Conclusions: The RIFLE classification for AKI appears to have prognostic utility in predicting mortality in patients with AML or HR-MDS. Relatively mild elevations in creatinine are associated with higher mortality. Strategies to avoid nephrotoxic drugs or fluid overload may be of benefit. Cancer 2010. (c) 2010 American Cancer Society.

Published
2010

110. Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers

Author

Sahajpal, Nikhil Shri, primary, Mondal, Ashis K., additional, Singh, Harmanpreet, additional, Vashisht, Ashutosh, additional, Ananth, Sudha, additional, Saul, Daniel, additional, Hastie, Alex R., additional, Hilton, Benjamin, additional, DuPont, Barbara R., additional, Savage, Natasha M., additional, Kota, Vamsi, additional, Chaubey, Alka, additional, Cortes, Jorge E., additional, and Kolhe, Ravindra, additional

Published
2023
Full Text
View/download PDF

111. Teledermatology for skin cancer screening in rural Georgia utilizing teledermoscopy and distance learning: An ongoing report

Author

Maloney, McKenzie E., primary, Miranda-Galvis, Marisol, additional, Juarez, Brenda Santellano, additional, Mamouni, Kenza, additional, Odhiambo, Lorriane, additional, Ibrahim, Samah, additional, Islam, K.M. Monirul, additional, Markowitz, Rhea-Beth, additional, Desai, Koosh, additional, Rabinovitz, Harold, additional, Buchanan, Kendall, additional, Patten, Douglas, additional, Davis, Loretta S., additional, and Cortes, Jorge E., additional

Published
2023
Full Text
View/download PDF

112. Supplementary Data from Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Author

Daver, Naval, primary, Garcia-Manero, Guillermo, primary, Basu, Sreyashi, primary, Boddu, Prajwal C., primary, Alfayez, Mansour, primary, Cortes, Jorge E., primary, Konopleva, Marina, primary, Ravandi-Kashani, Farhad, primary, Jabbour, Elias, primary, Kadia, Tapan, primary, Nogueras-Gonzalez, Graciela M., primary, Ning, Jing, primary, Pemmaraju, Naveen, primary, DiNardo, Courtney D., primary, Andreeff, Michael, primary, Pierce, Sherry A., primary, Gordon, Tauna, primary, Kornblau, Steven M., primary, Flores, Wilmer, primary, Alhamal, Zainab, primary, Bueso-Ramos, Carlos, primary, Jorgensen, Jeffrey L., primary, Patel, Keyur P., primary, Blando, Jorge, primary, Allison, James P., primary, Sharma, Padmanee, primary, and Kantarjian, Hagop, primary

Published
2023
Full Text
View/download PDF

113. Data from Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Author

Daver, Naval, primary, Garcia-Manero, Guillermo, primary, Basu, Sreyashi, primary, Boddu, Prajwal C., primary, Alfayez, Mansour, primary, Cortes, Jorge E., primary, Konopleva, Marina, primary, Ravandi-Kashani, Farhad, primary, Jabbour, Elias, primary, Kadia, Tapan, primary, Nogueras-Gonzalez, Graciela M., primary, Ning, Jing, primary, Pemmaraju, Naveen, primary, DiNardo, Courtney D., primary, Andreeff, Michael, primary, Pierce, Sherry A., primary, Gordon, Tauna, primary, Kornblau, Steven M., primary, Flores, Wilmer, primary, Alhamal, Zainab, primary, Bueso-Ramos, Carlos, primary, Jorgensen, Jeffrey L., primary, Patel, Keyur P., primary, Blando, Jorge, primary, Allison, James P., primary, Sharma, Padmanee, primary, and Kantarjian, Hagop, primary

Published
2023
Full Text
View/download PDF

115. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy

Author

Cortes, Jorge E., Heidel, Florian H., Fiedler, Walter, Smith, B. Douglas, Robak, Tadeusz, Montesinos, Pau, Candoni, Anna, Leber, Brian, Sekeres, Mikkael A., Pollyea, Daniel A., Ferdinand, Roxanne, Ma, Weidong Wendy, O’Brien, Thomas, O’Connell, Ashleigh, Chan, Geoffrey, and Heuser, Michael

Published
2020
Full Text
View/download PDF

117. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

Author

Cortes, Jorge E, De Souza, Carmino Antonio, Ayala, Manuel, Lopez, Jose Luis, Bullorsky, Eduardo, Shah, Sandip, Huang, Xiaojun, Babu, K Govind, Abdulkadyrov, Kudrat, de Oliveira, José Salvador Rodrigues, Shen, Zhi-Xiang, Sacha, Tomasz, Bendit, Israel, Liang, Zhizhou, Owugah, Tina, Szczudlo, Tomasz, Khanna, Sadhvi, Fellague-Chebra, Rafik, and le Coutre, Philipp D

Published
2016
Full Text
View/download PDF

118. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study

Author

Swords, Ronan T., Greenberg, Peter L., Wei, Andrew H., Durrant, Simon, Advani, Anjali S., Hertzberg, Mark S., Lewis, Ian D., Rivera, Gabriel, Gratzinger, Dita, Fan, Alice C., Felsher, Dean W., Cortes, Jorge E., Watts, Justin M., Yarranton, Geoff T., Walling, Jackie M., and Lancet, Jeffrey E.

Published
2016
Full Text
View/download PDF

120. Supplemental Methods and Tables from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models

Author

Benito, Juliana, primary, Ramirez, Marc S., primary, Millward, Niki Zacharias, primary, Velez, Juliana, primary, Harutyunyan, Karine G., primary, Lu, Hongbo, primary, Shi, Yue-xi, primary, Matre, Polina, primary, Jacamo, Rodrigo, primary, Ma, Helen, primary, Konoplev, Sergej, primary, McQueen, Teresa, primary, Volgin, Andrei, primary, Protopopova, Marina, primary, Mu, Hong, primary, Lee, Jaehyuk, primary, Bhattacharya, Pratip K., primary, Marszalek, Joseph R., primary, Davis, R. Eric, primary, Bankson, James A., primary, Cortes, Jorge E., primary, Hart, Charles P., primary, Andreeff, Michael, primary, and Konopleva, Marina, primary

Published
2023
Full Text
View/download PDF

121. Supplemental Figures 1-6 from Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models

Author

Benito, Juliana, primary, Ramirez, Marc S., primary, Millward, Niki Zacharias, primary, Velez, Juliana, primary, Harutyunyan, Karine G., primary, Lu, Hongbo, primary, Shi, Yue-xi, primary, Matre, Polina, primary, Jacamo, Rodrigo, primary, Ma, Helen, primary, Konoplev, Sergej, primary, McQueen, Teresa, primary, Volgin, Andrei, primary, Protopopova, Marina, primary, Mu, Hong, primary, Lee, Jaehyuk, primary, Bhattacharya, Pratip K., primary, Marszalek, Joseph R., primary, Davis, R. Eric, primary, Bankson, James A., primary, Cortes, Jorge E., primary, Hart, Charles P., primary, Andreeff, Michael, primary, and Konopleva, Marina, primary

Published
2023
Full Text
View/download PDF

122. Supplemental Table 1 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Author

Karjalainen, Katja, primary, Jaalouk, Diana E., primary, Bueso-Ramos, Carlos, primary, Bover, Laura, primary, Sun, Yan, primary, Kuniyasu, Akihiko, primary, Driessen, Wouter H.P., primary, Cardó-Vila, Marina, primary, Rietz, Cecilia, primary, Zurita, Amado J., primary, O'Brien, Susan, primary, Kantarjian, Hagop M., primary, Cortes, Jorge E., primary, Calin, George A., primary, Koivunen, Erkki, primary, Arap, Wadih, primary, and Pasqualini, Renata, primary

Published
2023
Full Text
View/download PDF

123. SuppData from Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS

Author

Savona, Michael R., primary, Pollyea, Daniel A., primary, Stock, Wendy, primary, Oehler, Vivian G., primary, Schroeder, Mark A., primary, Lancet, Jeffrey, primary, McCloskey, James, primary, Kantarjian, Hagop M., primary, Ma, Weidong Wendy, primary, Shaik, M. Naveed, primary, Laird, A. Douglas, primary, Zeremski, Mirjana, primary, O'Connell, Ashleigh, primary, Chan, Geoffrey, primary, and Cortes, Jorge E., primary

Published
2023
Full Text
View/download PDF

125. Supplemental Figure 2 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Author

Karjalainen, Katja, primary, Jaalouk, Diana E., primary, Bueso-Ramos, Carlos, primary, Bover, Laura, primary, Sun, Yan, primary, Kuniyasu, Akihiko, primary, Driessen, Wouter H.P., primary, Cardó-Vila, Marina, primary, Rietz, Cecilia, primary, Zurita, Amado J., primary, O'Brien, Susan, primary, Kantarjian, Hagop M., primary, Cortes, Jorge E., primary, Calin, George A., primary, Koivunen, Erkki, primary, Arap, Wadih, primary, and Pasqualini, Renata, primary

Published
2023
Full Text
View/download PDF

126. Supplemental Figure 1 from Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens

Author

Karjalainen, Katja, primary, Jaalouk, Diana E., primary, Bueso-Ramos, Carlos, primary, Bover, Laura, primary, Sun, Yan, primary, Kuniyasu, Akihiko, primary, Driessen, Wouter H.P., primary, Cardó-Vila, Marina, primary, Rietz, Cecilia, primary, Zurita, Amado J., primary, O'Brien, Susan, primary, Kantarjian, Hagop M., primary, Cortes, Jorge E., primary, Calin, George A., primary, Koivunen, Erkki, primary, Arap, Wadih, primary, and Pasqualini, Renata, primary

Published
2023
Full Text
View/download PDF

127. Data from KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors

Author

Corbin, Amie S., primary, O'Hare, Thomas, primary, Gu, Zhimin, primary, Kraft, Ira L., primary, Eiring, Anna M., primary, Khorashad, Jamshid S., primary, Pomicter, Anthony D., primary, Zhang, Tian Y., primary, Eide, Christopher A., primary, Manley, Paul W., primary, Cortes, Jorge E., primary, Druker, Brian J., primary, and Deininger, Michael W., primary

Published
2023
Full Text
View/download PDF

128. Supplementary Methods and Figures and Table from KIT Signaling Governs Differential Sensitivity of Mature and Primitive CML Progenitors to Tyrosine Kinase Inhibitors

Author

Corbin, Amie S., primary, O'Hare, Thomas, primary, Gu, Zhimin, primary, Kraft, Ira L., primary, Eiring, Anna M., primary, Khorashad, Jamshid S., primary, Pomicter, Anthony D., primary, Zhang, Tian Y., primary, Eide, Christopher A., primary, Manley, Paul W., primary, Cortes, Jorge E., primary, Druker, Brian J., primary, and Deininger, Michael W., primary

Published
2023
Full Text
View/download PDF

130. Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia

Author

Sweet, Kendra L., primary, Cortes, Jorge E., additional, Apperley, Jane F., additional, Mann, Mel, additional, Mauro, Michael J., additional, Oehler, Vivian G., additional, Ruiz, Cristina, additional, Schiffer, Charles A., additional, Ehrlich, Lori A., additional, Pamuk, Gulsum E., additional, Wynne, Joseph, additional, Mehta, Gautam U., additional, de Claro, R. Angelo, additional, Theoret, Marc R., additional, Smith, B. Douglas, additional, and Norsworthy, Kelly J., additional

Published
2023
Full Text
View/download PDF

136. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Author

Lipton, Jeffrey H, Chuah, Charles, Guerci-Bresler, Agnès, Rosti, Gianantonio, Simpson, David, Assouline, Sarit, Etienne, Gabriel, Nicolini, Franck E, le Coutre, Philipp, Clark, Richard E, Stenke, Leif, Andorsky, David, Oehler, Vivian, Lustgarten, Stephanie, Rivera, Victor M, Clackson, Timothy, Haluska, Frank G, Baccarani, Michele, Cortes, Jorge E, Guilhot, François, Hochhaus, Andreas, Hughes, Timothy, Kantarjian, Hagop M, Shah, Neil P, Talpaz, Moshe, and Deininger, Michael W

Published
2016
Full Text
View/download PDF

137. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Author

Deininger, Michael W., Hodgson, J. Graeme, Shah, Neil P., Cortes, Jorge E., Kim, Dong-Wook, Nicolini, Franck E., Talpaz, Moshe, Baccarani, Michele, Müller, Martin C., Li, Jin, Parker, Wendy T., Lustgarten, Stephanie, Clackson, Tim, Haluska, Frank G., Guilhot, Francois, Kantarjian, Hagop M., Soverini, Simona, Hochhaus, Andreas, Hughes, Timothy P., Rivera, Victor M., and Branford, Susan

Published
2016
Full Text
View/download PDF

146. Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Author

Cortes, Jorge E., primary, Hughes, Timothy, additional, Geissler, Jan, additional, Kim, Dong-Wook, additional, Lomaia, Elza, additional, Mayer, Jiri, additional, Turkina, Anna G., additional, Hurwicz Kogut, Sarah, additional, Torres Cardoso, Ana Paula, additional, Sura, Monali, additional, and Saglio, Giuseppe, additional

Published
2022
Full Text
View/download PDF

147. Long-Term Results of the Treatment of Adolescents and Adults with Acute Lymphoblastic Leukemia with a Pediatric-Inspired Regimen Delivered on an Outpatient Basis: A Single Institution Experience

Author

García-Villaseñor, Elizabeth, primary, Cortes, Jorge E., additional, Reyes-Cisneros, Oscar A., additional, Fernández-Gutiérrez, José Antonio, additional, Sánchez-Bonilla, Daniela, additional, Bojalil-Álvarez, Lorena, additional, Murrieta-Álvarez, Iván, additional, Ruiz-Delgado, Guillermo José, additional, and Ruiz Argüelles, Guillermo José, additional

Published
2022
Full Text
View/download PDF

148. Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Author

Mauro, Michael, primary, Paquette, Ronald, additional, Hehlmann, Rüdiger, additional, Williams, Loretta A., additional, Goldberg, Stuart L., additional, Michallet, Mauricette, additional, Gambacorti-Passerini, Carlo, additional, Tang, Derek, additional, DeGutis, Irene S., additional, McBride, Ali, additional, Parsons, Lori, additional, Montelongo, Monica Z., additional, and Cortes, Jorge E., additional

Published
2022
Full Text
View/download PDF

150. A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Author

Ong, Faustine, primary, Garcia-Manero, Guillermo, additional, Montalban-Bravo, Guillermo, additional, Alvarado, Yesid, additional, Ohanian, Maro, additional, Konopleva, Marina, additional, Jabbour, Elias, additional, Jain, Nitin, additional, Borthakur, Gautam, additional, DiNardo, Courtney D., additional, Daver, Naval, additional, Issa, Ghayas C., additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Takahashi, Koichi, additional, Andreeff, Michael, additional, Muftuoglu, Muharrem, additional, Delumpa, Ricardo, additional, Mayor, Ejiroghene, additional, Loiselle, Christopher, additional, Waller, Lourdes, additional, Banks, Glenda, additional, Kantarjian, Hagop, additional, Cortes, Jorge E., additional, and Short, Nicholas, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results